ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / HALO / options
NBIX (73) EXEL (89) TWST (52) TECH (72) ⌘ Pro Terminal →

Halozyme Therapeutics Inc. (HALO) Options Positioning, Max Pain & Unusual Sweeps

$130.91 -0.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $131.17

Halozyme Therapeutics Inc. (HALO) earns a Roarable Rating of B (Buy) with 75/100 RQD Confidence. High-quality cash engine (84% profit margin, 18% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 75/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.4% avg 90D alpha vs SPY • 69.7% hit rate) →
ROARABLE B • BUY Cap $14.89B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HALO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HALO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Halozyme Therapeutics Inc. (NASDAQ: HALO) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $130.91 (-0.21% 1D, market cap $14.89B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, HALO ranks #39 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HALO compare to NBIX and EXEL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), HALO carries a Roarable B (75/100 RQD), trailing P/E of 47.0x, gross margin of 83.6%, and ROIC of 18.0%. By comparison, NBIX (Neurocrine Biosciences Inc.) holds a B grade (73/100 RQD, P/E 31.1x, ROIC 15.7%, cap $14.88B) and EXEL (Exelixis Inc.) posts a A grade (89/100 RQD, P/E 21.0x, ROIC 35.1%, cap $16.40B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HALO?
▼

Per HALO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001159036), Halozyme Therapeutics Inc. generated $1.40B in revenue (+37.6% YoY), $316.9M in net income, and $644.6M in free cash flow against $2.53B in total assets and $2.14B in total debt. Key quantitative strengths: Strong cash generator (84% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $131.17 (+0.20%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 46.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 75/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.4% avg 90D alpha vs SPY • 69.7% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510075
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk C
Cash (18)Whales (18)SEC (15)Macro (11)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+7.6% Base Target
$166 Bull$141 Base$107 Bear
📬 FREE HALO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HALO)Realized 20D OHLCV Swing Band: ±5.8%
Deterministic 5-Pillar Attribution (75/100 Composite)
🔍 WHY HALO SCORES 75/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 46.2% FCF Margin ($644.6M FCF) & 83.6% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+18/20 pts (24% of score)

20D Institutional Volume Accumulation (±5.8% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit11/20 pts (-9 pt drag)

Macro rate sensitivity & RSI-14 (79) create a -9 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
67
Grade B-$109.62+13.5% Next Q
Q2 (-2Q)
70
Grade B$124.37+3.3% Next Q
Q3 (-1Q)
72
Grade B$128.50+1.9% Next Q
Current
75
Grade B$130.91+7.4% Hist 90D α
Trajectory: B- (67) → B (75)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the HALO Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 75/100 (B) score, HALO faces multiple-compression risk if 47.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 81.1% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($114.61) or 200D SMA ($83.97) invalidates the momentum regime and cuts Target Base ($140.92) toward Bear Floor ($107.35).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HALO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HALO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 75%NO 25%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±5.8%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (HALO)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for HALO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating HALO & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on HALO
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
HALO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +102.74%⚡ TESTING RESISTANCE
2026-11-02O $130.0H $131.2L $130.0C $130.9VOL 1.88M
RES: $135.2SUP: $96.19SMA50: $114.6SMA200: $83.97
$139.0$118.4$97.85$77.29$56.73RES $135.2SUP $96.19$130.92026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HALO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HALO Butterfly Map → + Track HALO →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
34.7%/yr Implied 5Y Growth

vs. +37.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HALO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HALO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HALO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HALO)

Health Care Rank #39 of 1016 ⚔️ NBIX vs HALO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HALO vs. NBIX, EXEL, TWST, TECH)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Halozyme Therapeutics Inc. (HALO) ranks #39 by composite RQD confidence (75/100, grade B) and #80 by equity capitalization ($14.89B). Within this direct 5-issuer industry benchmark cohort, EXEL leads on earnings valuation at 21.0x trailing P/E, while EXEL leads on capital efficiency and profitability with 35.1% ROIC and 96.0% gross margin. EXEL currently holds the highest overall quantitative score in the immediate peer group at 89/100 (A) compared with HALO at 75/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
HALO ACTIVE
Halozyme Therapeutics Inc.
B 75/100 47.0x 83.6% 18.0% -0.21% $14.89B Benchmark Subject
NBIX
Neurocrine Biosciences Inc.
B 73/100 31.1x 96.0% 15.7% -0.19% $14.88B /nbix-vs-halo →
EXEL
Exelixis Inc.
A 89/100 21.0x 96.0% 35.1% +4.82% $16.40B /exel-vs-halo →
TWST
Twist Bioscience Corporation
D+ 52/100 — 94.2% -11.7% -11.92% $11.50B /twst-vs-halo →
TECH
Bio-Techne Corp
B 72/100 155.3x 64.8% 3.4% -0.07% $11.40B /tech-vs-halo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001159036

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Halozyme Therapeutics Inc. (HALO) reported GAAP revenue of $1.40B (+37.6% vs. FY2024 revenue of $1.02B , and +68.4% cumulative change since FY2023) , GAAP net income of $316.9M, operating cash flow of $651.6M, and free cash flow of $644.6M (+37.6% YoY). On the balance sheet, HALO closed FY2025 with $2.53B in total assets against $2.14B in total debt (Altman Z-Score: 5.11, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.40B $316.9M $651.6M $644.6M $2.53B $2.14B
FY2024 (FY) 2024-12-31 $1.02B $444.1M $479.1M $468.4M $2.06B $1.51B
FY2023 (FY) 2023-12-31 $829.3M $281.6M $388.6M $351.3M $8.19B $1.92B

3. HALO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HALO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Halozyme Therapeutics Inc. (NASDAQ: HALO) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $130.91 (-0.21% 1D, market cap $14.89B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, HALO ranks #39 in composite RQD confidence.

How does HALO compare to NBIX and EXEL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), HALO carries a Roarable B (75/100 RQD), trailing P/E of 47.0x, gross margin of 83.6%, and ROIC of 18.0%. By comparison, NBIX (Neurocrine Biosciences Inc.) holds a B grade (73/100 RQD, P/E 31.1x, ROIC 15.7%, cap $14.88B) and EXEL (Exelixis Inc.) posts a A grade (89/100 RQD, P/E 21.0x, ROIC 35.1%, cap $16.40B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HALO?

Per HALO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001159036), Halozyme Therapeutics Inc. generated $1.40B in revenue (+37.6% YoY), $316.9M in net income, and $644.6M in free cash flow against $2.53B in total assets and $2.14B in total debt. Key quantitative strengths: Strong cash generator (84% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HALO trading relative to its 50-day, 200-day, and 52-week technical levels?

HALO last traded at $130.91 (-0.21% on volume of 1,402,663 shares), positioning the stock +14.22% above its 50-day simple moving average ($114.61) and +55.90% above its 200-day simple moving average ($83.97). Across its 52-week range of $61.23 to $134.00, HALO sits at the 95.8% percentile with a 14-day RSI of 79.0 (OVERBOUGHT (>70)) and an implied next-earnings move of ±5.8% ($123.32 to $138.50).

HALO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is HALO's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for HALO.

Direct Sub-Reports: HALO RQD Cockpit HALO 12M Forecast HALO Earnings & Move HALO Dividends & DRIP HALO Insiders & 13F HALO Whale Options HALO Profit Sankey HALO News & Why
ROARABLE RATING BRIEF • RQD 75/100 (B) ✓ STAGE-C NUMBER FIREWALL VERIFIED

HALO — Halozyme Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:14:44Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, HALO scores 75 out of 100, a letter grade of B, labeled "Roarable Buy — Good Risk/Reward." The five pillars are:

  • Fundamental Cash Engine: 18 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 18% and an FCF yield of 4.33%. For a prospective investor, this is the strongest support for the rating: the business converts capital into returns at a high rate, though the 4.33% FCF yield indicates the market is pricing the stock at a rich multiple of current cash generation.
  • Whale 13F Flow: 18 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. The source data does not itemize the underlying 13F or options figures, so the score cannot be decomposed further here.
  • Insider Conviction: 13 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. This is a moderate reading, suggesting insider signals are supportive but not decisively so.
  • Macro Regime Fit: 11 / 20. Per the Roarable RQD rating, this pillar reflects a beta of 0.88 and sector sensitivity. A beta below 1 implies below-market sensitivity to broad moves, a defensive feature, yet the pillar's below-midpoint score signals weaker fit with the current macro backdrop.
  • Forensic Balance Sheet: 15 / 20. Per the Roarable RQD rating, this pillar reflects an Altman Z of 5.11, a Piotroski F of 7/9, and Debt/Equity of 8.5. The Z and F readings are favorable; the leverage figure is the principal caution.

Taken together, the rating points to quality operations and institutional support offset by valuation (P/E TTM of 47) and macro-fit weakness. Valuation tradeoffs are central: the stock trades at a premium multiple, so upside depends on sustained earnings growth.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$131.18$14.89B4739.535.62.790%0.88$61.23 - $13418%

Business

Per the profile, Halozyme Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Biological Products (No Diagnostic Substances). Per the profile, its market capitalization is $14.9B. Not available in source data: product lines, customer base, and revenue mix. The source data does not describe how the company generates revenue beyond its sector and industry classification.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$1396.6M$469.0M$316.9MN/A$644.6M$133.8M$2142.6M
FY 2024$1015.3M$551.5M$444.1MN/A$468.4M$115.8M$1505.8M
FY 2023$829.3M$337.6M$281.6MN/A$351.3MN/A$1916.2M

Per the SEC financials, revenue rose from $829.3M in FY 2023 to $1396.6M in FY 2025, while FCF rose from $351.3M to $644.6M. Per the market data, gross margin is 83.6%, operating margin 33.6%, and net margin 22.7%, with ROIC of 18%. Per the Roarable RQD rating, the Altman Z-Score is 5.11 and the Piotroski F-Score is 7/9, both supportive readings. Debt rose from $1916.2M (FY 2023) to $2142.6M (FY 2025), and the Debt/Equity of 8.5 per the RQD pillar data signals meaningful leverage. Net income declined from $444.1M in FY 2024 to $316.9M in FY 2025 even as revenue grew.

Recent Catalysts & News Wire Analysis

Per the recent news feed, six items reference HALO:

  • CATALYST (GREEN): An earnings-expectations preview ("Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?") and a report on strong earnings growth sending shares higher.
  • RISK WATCH (RED): A Trefis piece asking what investors missed before a run, flagged as a risk item.
  • MARKET WIRE (YELLOW): Items from Yahoo! Finance Canada, ChartMill (a value/profitability note), and Investing.com (a note on the stock climbing).

Per the Butterfly supply-chain graph, the supply chain is listed as "NONE," with no butterfly links and no proprietary signals. The catalyst picture is therefore headline-level only; the source data does not establish the earnings dates, magnitudes, or the content of the risk item.

Open Questions

  • What drove the decline in net income from $444.1M (FY 2024) to $316.9M (FY 2025) despite revenue growth?
  • What is the composition of the $2142.6M debt, and what is the debt maturity and interest-cost profile?
  • What were the actual earnings results and magnitudes behind the "strong earnings growth" headline?
  • What is the company's product and revenue mix, which the source data does not describe?
  • What are the specific 13F, options, and insider transactions underlying the RQD flow pillars?

HALO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Halozyme Therapeutics Inc. (HALO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HALO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HALO Bull vs. Bear Conversation Board — What's Your Call at $130.91?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HALO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on HALO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $154.79 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is HALO (B • RQD 75/100) a Buy at $131.18?

Welcome to the HALO (Halozyme Therapeutics Inc.) Roar Pit. Current RQD Composite is 75/100 (Roarable Buy — Good Risk/Reward) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to capital efficiency (18.0% ROIC), while bears focus on valuation multiple compression (47.0x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $99.70 (-24.0%)
Spot @ $131.18

Pump the brakes on HALO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on HALO, but look at what you are paying: 47.0x trailing P/E with 83.6% gross margins. Unless Halozyme Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $166.60 (+27.0%)
Spot @ $131.18

HALO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on HALO, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $131.18 (52-wk range $61.23 - $134.00), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%